<DOC>
	<DOCNO>NCT01438996</DOCNO>
	<brief_summary>The purpose study evaluate immunogenicity kinetics anti-Vi antibody response follow secondary vaccination Novartis Vaccines Institute Global Health ( NVGH ) Vi-CRM197 vaccine healthy adult previously vaccinate either NVGH Vi-CRM197 Vi-polysaccharide ( Typherix ) H01_04TP study ( NCT01193907 ) immunogenicity kinetics anti-Vi antibody response follow primary vaccination NVGH Vi-CRM197 vaccine naïve healthy adult .</brief_summary>
	<brief_title>Extension Study H01_04TP Evaluate Booster Response Induced Vi-CRM197 Adults</brief_title>
	<detailed_description />
	<mesh_term>Typhoid Fever</mesh_term>
	<criteria>Inclusion criterion All Subjects : 1 . Males females age ≥18 ≤42 year . 2 . Individuals , , nature study explain , give write consent accord local regulatory requirement . 3 . Individuals good health determine outcome medical history , physical examination clinical judgment investigator . 4 . If woman , use birth control one month study start , negative pregnancy test willingness use birth control measure entire study duration . H01_04TP subject : 5 . Individuals previously participate H01_04TP study vaccinate either NVGH ViCRM197 ( 5μg ) license ViPS . 6 . Individuals receive Vi vaccination subsequent one receive H01_04TP study . Inclusion criteria All subject : 1 . Individuals behavioral cognitive impairment psychiatric disease , opinion investigator , may interfere subject 's ability participate study . 2 . Individuals progressive severe neurological disorder , seizure disorder GuillainBarré syndrome . 3 . Individuals able understand follow require study procedure whole period study . 4 . Individuals history illness , opinion investigator , pose additional risk subject due participation study . 5 . Individuals know suspected HIV infection HIV related disease , history autoimmune disorder know suspected impairment /alteration immune system , immunosuppressive therapy include use systemic corticosteroid chronic use inhale highpotency corticosteroid within previous 30 day , chemotherapy treatment within past 6 month . 6 . Individuals know bleed diathesis , condition may associate prolonged bleeding time . 7 . Individuals serious chronic progressive disease accord judgment investigator ( e.g. , neoplasm , insulin dependent diabetes , cardiac , renal hepatic disease ) . 8 . Individuals malignancy lymphoproliferative disorder . 9 . Individuals history allergy vaccine component . 10 . Individuals participate clinical trial another investigational product 30 day prior first study visit intent participate another clinical study time conduct study . 11 . Individuals receive vaccine within 4 week prior enrolment study plan receive vaccine within 4 week study vaccine 12 . Individuals receive blood , blood product and/or plasma derivative include parenteral immunoglobulin preparation past 12 week . 13 . Individuals part study personnel close family member personnel conduct study . 14 . Individuals body temperature &gt; 38.0 degree Celsius within 3 day intend study immunization . 15 . BMI &gt; 35 kg/m2 . 16 . Individuals history substance alcohol abuse within past 2 year . 17 . Women pregnant breastfeed childbearing age use birth control measure one month prior study start plan use acceptable birth control measure , duration study . 18 . Females history stillbirth , neonatal loss , previous infant anomaly . 19 . Individuals previously ascertain suspected disease cause S. Typhi . 20 . Individuals household contact with/and intimate exposure individual laboratory confirm S. Typhi . 21 . Any condition , opinion investigator may interfere evaluation study objective . Naïve subject : 22 . Individuals previously receive vaccine typhoid fever ( either oral live attenuate injectable vaccine )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>42 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Typhoid fever</keyword>
	<keyword>Glycoconjugate vaccine</keyword>
	<keyword>Vi polysaccharide</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>